Monitoring MRD with flow cytometry: An effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 183-192

  Zhao, Xiao Su ^a   Liu, Yan Rong ^a   Zhu, Hong Hu ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Liu, Kai Yan ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute lymphoblastic leukemia; Flow cytometry; Hematopoietic stem cell transplantation; Minimal residual disease; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; FLUDARABINE; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RELAPSE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84857365039     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1285-1     Document Type: Article

References (35)

1. I Avivi JM Rowe AH Goldstone 2002 Stem cell transplantation in adult ALL patients Best Practice Res 15 4 653 674 1:CAS:528:DC%2BD3sXhs1Cht7c%3D
2. P Bader J Hancock H Kreyenberg NJ Goulden D Niethammer A Oakhill CG Steward R Handgretinger JF Beck T Klingebiel 2002 Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL Leukemia 16 9 1668 1672 12200679 10.1038/sj.leu.2402552 1:STN:280:DC%2BD38vkt1yjsg%3D%3D
3. MJ Borowitz M Devidas SP Hunger WP Bowman AJ Carroll WL Carroll S Linda PL Martin DJ Pullen D Viswanatha CL Willman N Winick BM Camitta 2008 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood 111 12 5477 5485 18388178 10.1182/blood-2008-01-132837 1:CAS:528:DC%2BD1cXnsVOkt74%3D
4. MJ Borowitz DJ Pullen JJ Shuster D Viswanatha K Montgomery CL Willman B Camitta 2003 Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study Leukemia 17 8 1566 1572 12886244 10.1038/sj.leu.2403001 1:STN:280:DC%2BD3szltlKlug%3D%3D (Pubitemid 36986959)
5. M Bruggemann T Raff T Flohr N Gokbuget M Nakao J Droese S Luschen C Pott M Ritgen U Scheuring HA Horst E Thiel D Hoelzer CR Bartram M Kneba 2006 Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood 107 3 1116 1123 16195338 10.1182/blood-2005-07-2708 (Pubitemid 43156313)
6. N Bunin DA Johnston WM Roberts MV Ouspenskaia VZ Papusha MA Brandt TF Zipf 2003 Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features Br J Haematol 120 4 711 715 12588362 10.1046/j.1365-2141. 2003.04135.x (Pubitemid 36255876)
7. D Campana 2004 Minimal residual disease studies in acute leukemia Am J Clin Pathol 122 Suppl S47 S57 15690642
8. D Campana E Coustan-Smith 2004 Minimal residual disease studies by flow cytometry in acute leukemia Acta Haematol 112 1-2 8 15 15178999 10.1159/000077554 (Pubitemid 38716244)
9. D Campana GA Neale E Coustan-Smith CH Pui 2001 Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience Leukemia 15 2 278 279 11236945 10.1038/sj.leu.2402021 1:STN:280: DC%2BD3M7otVyksg%3D%3D (Pubitemid 32175461)
10. J Ciudad JF San Miguel MC Lopez-Berges B Vidriales B Valverde M Ocqueteau G Mateos MD Caballero J Hernandez MJ Moro MV Mateos A Orfao 1998 Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia J Clin Oncol 16 12 3774 3781 9850021 1:STN:280: DyaK1M%2FmsFaksQ%3D%3D (Pubitemid 29001529)
11. E Coustan-Smith FG Behm J Sanchez JM Boyett ML Hancock SC Raimondi JE Rubnitz GK Rivera JT Sandlund CH Pui D Campana 1998 Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 351 9102 550 554 9492773 10.1016/S0140-6736(97)10295-1 1:STN:280: DyaK1c7ltlOhsg%3D%3D (Pubitemid 28077560)
12. E Coustan-Smith J Sancho FG Behm ML Hancock BI Razzouk RC Ribeiro GK Rivera JE Rubnitz JT Sandlund CH Pui D Campana 2002 Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood 100 1 52 58 12070008 10.1182/blood-2002-01-0006 1:CAS:528:DC%2BD38XltF2rs7s%3D (Pubitemid 35177428)
13. E Coustan-Smith J Sancho ML Hancock JM Boyett FG Behm SC Raimondi JT Sandlund GK Rivera JE Rubnitz RC Ribeiro CH Pui D Campana 2000 Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 96 8 2691 2696 11023499 1:CAS:528:DC%2BD3cXnt12gsLY%3D
14. MN Dworzak G Froschl D Printz G Mann U Potschger N Muhlegger G Fritsch H Gadner 2002 Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood 99 6 1952 1958 11877265 10.1182/blood.V99.6.1952 1:CAS:528:DC%2BD38XitF2nt70%3D (Pubitemid 34525474)
15. MN Dworzak ER Panzer-Grumayer 2003 Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia Leuk Lymphoma 44 9 1445 1455 14565643 10.1080/1042819031000090174 (Pubitemid 36833955)
16. H Glucksberg R Storb A Fefer CD Buckner PE Neiman RA Clift KG Lerner ED Thomas 1974 Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 4 295 304 4153799 10.1097/00007890-197410000-00001 1:STN:280:DyaE2M%2Fis1Wjsw%3D%3D
17. XJ Huang DH Liu KY Liu LP Xu H Chen W Han YH Chen XH Zhang DP Lu 2009 Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation Biol Blood Marrow Transplant 15 2 257 265 19167686 10.1016/j.bbmt.2008.11.025 1:CAS:528:DC%2BD1MXjtVyiur4%3D
18. CJ Knechtli NJ Goulden JP Hancock EL Harris RJ Garland CG Jones VL Grandage AW Rowbottom AF Green E Clarke AW Lankester MN Potter JM Cornish DH Pamphilon CG Steward A Oakhill 1998 Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia Br J Haematol 102 3 860 871 9722317 10.1046/j.1365-2141.1998.00873.x 1:STN:280:DyaK1czoslOksA%3D%3D (Pubitemid 28387073)
19. KN Koh M Park BE Kim HJ Im CJ Park S Jang HS Chi JJ Seo 2010 Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia Korean J Pediatr 53 11 957 964 10.3345/kjp. 2010.53.11.957 21218018 10.3345/kjp.2010.53.11.957
20. YR Liu LP Zhang Y Chang YF Cheng JY Fu LD Li H Wang GL Liu SS Chen XJ Huang DP Lu 2006 Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia Chin J Hematol 27 5 302 305 1:CAS:528:DC%2BD2sXhtFGmur7E
21. M Malec E Bjorklund S Soderhall J Mazur AM Sjogren P Pisa M Bjorkholm A Porwit-MacDonald 2001 Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL Leukemia 15 5 716 727 11368431 10.1038/sj.leu.2402091 1:CAS:528:DC%2BD3MXks1Kks74%3D (Pubitemid 32492694)
22. G Mitterbauer P Nemeth S Wacha NC Cross I Schwarzinger U Jaeger K Geissler HT Greinix P Kalhs K Lechner C Mannhalter 1999 Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction Br J Haematol 106 3 634 643 10468851 10.1046/j.1365-2141.1999.01605.x 1:STN:280: DyaK1MzpvVSktQ%3D%3D (Pubitemid 29434200)
23. FY Mortuza M Papaioannou IM Moreira LA Coyle P Gameiro D Gandini HG Prentice A Goldstone AV Hoffbrand L Foroni 2002 Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia J Clin Oncol 20 4 1094 1104 11844835 10.1200/JCO.20.4. 1094 (Pubitemid 34141855)
24. L Munoz O Lopez R Martino S Brunet M Bellido E Rubiol J Sierra JF Nomdedeu 2000 Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia Haematologica 85 7 704 710 10897122 1:CAS:528:DC%2BD3cXntFCgs7w%3D (Pubitemid 30617104)
25. A Nagler R Condiotti R Rabinowitz M Schlesinger M Nguyen LW Terstappen 1999 Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC) Med Oncol (Northwood, London, England) 16 3 177 187 10.1007/BF02906129 1:STN:280:DyaK1Mvls1ehtg%3D%3D (Pubitemid 29466093)
26. GA Neale E Coustan-Smith P Stow Q Pan X Chen CH Pui D Campana 2004 Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 18 5 934 938 15029212 10.1038/sj.leu.2403348 1:CAS:528: DC%2BD2cXjtlyitLg%3D (Pubitemid 38714617)
27. C Preudhomme N Henic B Cazin JL Lai MF Bertheas M Vanrumbeke F Lemoine JP Jouet E Deconninck B Nelken A Cosson P Fenaux 1997 Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) Leukemia 11 2 294 298 9009095 10.1038/sj.leu.2400567 1:CAS:528:DyaK2sXotVSgtrs%3D (Pubitemid 27085176)
28. YZ Qin JL Li HH Zhu LD Li Y Chang H Le GR Ruan YR Liu XJ Huang SS Chen 2007 Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique Chin J Hematol 28 7 433 437 1:CAS:528:DC%2BD1cXotFWqt7Y%3D
29. YZ Qin YR Liu HH Zhu JL Li GR Ruan Y Zhang Q Jiang H Jiang LD Li Y Chang XJ Huang SS Chen 2008 Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response Int J Lab Hematol 30 4 317 323 18665830 10.1111/j.1751-553X.2007.00962.x 1:STN:280:DC%2BD1cvosFKhsQ%3D%3D
30. J Sanchez J Serrano P Gomez F Martinez C Martin L Madero C Herrera JM Garcia J Casano A Torres 2002 Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation Br J Haematol 116 3 686 694 11849234 10.1111/j.1365-2141.2002. 3311a.x (Pubitemid 34178675)
31. O Spinelli B Peruta M Tosi V Guerini A Salvi MC Zanotti E Oldani A Grassi T Intermesoli C Mico G Rossi P Fabris G Lambertenghi-Deliliers E Angelucci T Barbui R Bassan A Rambaldi 2007 Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia Haematologica 92 5 612 618 17488684 10.3324/haematol.10965 (Pubitemid 350144263)
32. T Szczepanski 2007 Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 21 4 622 626 17301806 1:STN:280:DC%2BD2s7ntV2jtw%3D%3D (Pubitemid 46444543)
33. VH van der Velden JM Wijkhuijs JJ van Dongen 2008 Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring Leukemia 22 3 641 644 17851557 10.1038/sj.leu.2404925 (Pubitemid 351386738)
34. MB Vidriales JJ Perez MC Lopez-Berges N Gutierrez J Ciudad P Lucio L Vazquez R Garcia-Sanz MC del Canizo J Fernandez-Calvo F Ramos MJ Rodriguez MJ Calmuntia A Porwith A Orfao JF San-Miguel 2003 Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood 101 12 4695 4700 12586618 10.1182/blood-2002-08-2613 1:CAS:528:DC%2BD3sXkslequ70%3D (Pubitemid 36857722)
35. EG Weir K Cowan P LeBeau MJ Borowitz 1999 A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection Leukemia 13 4 558 567 10214862 10.1038/sj.leu.2401364 1:STN:280: DyaK1M3ivFKktw%3D%3D (Pubitemid 29195284)